Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Gelbenegger

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Critical Care Medicine|October 7, 2025
The authors replyGeorg Gelbenegger, Anselm Jorda
Expert Review of Clinical Pharmacology|September 6, 2022
Clinical pharmacology of antiplatelet drugsGeorg Gelbenegger, Bernd Jilma
Critical Care Medicine|November 20, 2025
The authors replyAnselm Jorda, Georg Gelbenegger
Expert Opinion on Biological Therapy|May 2, 2023
Monoclonal antibodies for treatment of cold agglutinin diseaseGeorg Gelbenegger, Sigbjørn Berentsen, Bernd Jilma
Thrombosis and Haemostasis|July 28, 2020
Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia AGeorg Gelbenegger, Christian Schoergenhofer, Paul Knoebl, et al.
British Journal of Clinical Pharmacology|November 12, 2022
Management of acquired haemophilia A in severe Covid-19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosisGeorg Gelbenegger, Ludwig Traby, Nina Rahimi, et al.
Vaccines|September 28, 2021
Rhabdomyolysis Following Ad26.COV2.S COVID-19 VaccinationGeorg Gelbenegger, Filippo Cacioppo, Christa Firbas, et al.
Lancet (London, England)|July 20, 2024
Patient-level and trial-level data meta-analysesAnselm Jorda, Markus Zeitlinger, Bernd Jilma, et al.
Drug Safety - Case Reports|November 5, 2017
Severe Hypernatraemic Dehydration and Unconsciousness in a Care-Dependent Inpatient Treated with EmpagliflozinGeorg Gelbenegger, Nina Buchtele, Christian Schoergenhofer, et al.
Clinical Pharmacology and Therapeutics|December 4, 2021
Anticoagulant Treatment Regimens in Patients With Covid-19: A Meta-AnalysisAnselm Jorda, Jolanta M Siller-Matula, Markus Zeitlinger, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Critical Care Medicine|October 7, 2025
The authors replyGeorg Gelbenegger, Anselm Jorda
Expert Review of Clinical Pharmacology|September 6, 2022
Clinical pharmacology of antiplatelet drugsGeorg Gelbenegger, Bernd Jilma
Critical Care Medicine|November 20, 2025
The authors replyAnselm Jorda, Georg Gelbenegger
Expert Opinion on Biological Therapy|May 2, 2023
Monoclonal antibodies for treatment of cold agglutinin diseaseGeorg Gelbenegger, Sigbjørn Berentsen, Bernd Jilma
Thrombosis and Haemostasis|July 28, 2020
Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia AGeorg Gelbenegger, Christian Schoergenhofer, Paul Knoebl, et al.
British Journal of Clinical Pharmacology|November 12, 2022
Management of acquired haemophilia A in severe Covid-19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosisGeorg Gelbenegger, Ludwig Traby, Nina Rahimi, et al.
Vaccines|September 28, 2021
Rhabdomyolysis Following Ad26.COV2.S COVID-19 VaccinationGeorg Gelbenegger, Filippo Cacioppo, Christa Firbas, et al.
Lancet (London, England)|July 20, 2024
Patient-level and trial-level data meta-analysesAnselm Jorda, Markus Zeitlinger, Bernd Jilma, et al.
Drug Safety - Case Reports|November 5, 2017
Severe Hypernatraemic Dehydration and Unconsciousness in a Care-Dependent Inpatient Treated with EmpagliflozinGeorg Gelbenegger, Nina Buchtele, Christian Schoergenhofer, et al.
Clinical Pharmacology and Therapeutics|December 4, 2021
Anticoagulant Treatment Regimens in Patients With Covid-19: A Meta-AnalysisAnselm Jorda, Jolanta M Siller-Matula, Markus Zeitlinger, et al.
Pageof 6